secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOTRICITY INC. (BTCY)
CIK:        0001630113
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0001493152-24-046908
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biotricity Q2 FY2025 revenue up 13% YoY to $3.3M; net loss down 57% to $1.65M
-----------------------------------------------------------------------------

- Revenue $3.3M (+13% YoY); gross margin improved to 75.3% from 69.1%.
- Net loss decreased 57% to $1.65M ($0.073/share) from $3.88M in Q2 FY24.
- Recurring tech fees $3.06M (+12.2%), 94% of total revenue; flat fee portion up 34%.
- Achieved positive cash flow on current operating basis in September; expects continued improvement.
- SG&A cut 35.5% to $2.25M; total operating expenses down 34% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630113/000149315224046908/0001493152-24-046908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630113/000149315224046908/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-046908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer